Evidence map›Paper›PMID 40144427›Full record

ArticleCureus2025

A Case Report of a Rapid Development of Hepatocellular Carcinoma (HCC) Within Six Months of Hepatitis C Cure in an Individual With Risk Factors.

Muhammad A Israr

Abstract readCase Reports
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Muhammad A IsrarInternal Medicine, Fairfield Medical Center, Lancaster, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

People with chronic liver disease are more likely to develop hepatocellular carcinoma (HCC), especially those with cirrhosis or fibrosis. Confounding variables, such as alcohol consumption, end-stage renal disease, and poorly controlled diabetes mellitus, can lead to detrimental outcomes such as the development of HCC since the liver is already damaged and in a recovery phase from the resolved hepatitis C infection. HCC should be a high differential diagnosis even in the absence of classical signs and symptoms of jaundice or weight loss given the resolved hepatitis C infection. In this case study, a 63-year-old male with a past medical history of intravenous (IV) drug use, chronic alcoholic cirrhosis, end-stage renal disease, and cured hepatitis C infection presented at the primary care office for a regular follow-up visit after getting discharged from the emergency department (ED). During a routine primary care visit, the patient complained of right upper quadrant pain, constipation, and intermittent dizziness. At the time, he also endorsed drinking a case of beer daily and a fifth of liquor monthly. He had a history of hepatitis C, which he acquired through IV drug use. He was successfully treated with a six-month course of glecaprevir/pibrentasvir with eradication of the virus. Before the primary care practitioner (PCP) visit, the patient had an ED visit for abdominal pain and chronic constipation, during which he underwent a non-contrast CT of the abdomen, with an incidental finding of a 2.4 cm liver mass in the right hepatic lobe. It was followed up with an MRI and CT-guided biopsy, the results of which showed poorly differentiated HCC.

Indexed as

alcoholic cirrhosisgastrointestinal oncologyhepatitis c (hcv) infectionhepatocellular carcinoma (hcc)injection drug use

Identifiers

PMID40144427
PMCPMC11940550

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.